Paysign Shatters Records, Raises Outlook as Patient Affordability Momentum Continues
Paysign, a leading provider of patient affordability solutions, has announced its second quarter 2026 earnings results, shattering records for revenue, net income, and adjusted EBITDA. The company's continued momentum reflects the strategic decision to invest in patient affordability as a business that complements plasma and augments overall growth.
According to Mr. Mark Newcomer, President and CEO of Paysign, "the momentum we're seeing reflects the strategic decision we made a few years ago to invest in patient affordability as a business that could complement plasma and augment our overall growth trajectory." He noted that this quarter is a good example of that work continuing to pay off.
The company's revenue grew 48% year-over-year to $28.3 million, while net income came in at $6.8 million, or $0.11 per fully diluted share, a near five-fold increase year-over-year. Gross margin expanded 170 basis points to 63.3%. Patient affordability delivered another exceptional quarter and remains the company's principal growth engine.
Revenue rose 89% year-over-year to $14.6 million, with claim volume approximately 54% higher than the second quarter of last year. This reflects the compounding effect of new program wins, deeper utilization across existing clients, and the continued expansion of largest pharmaceutical partnerships. Paysign is scaling the business methodically, and the combination of strong growth, margin expansion, and positive contribution margin demonstrates that strategy is working.
The company's plasma business also expanded margin this quarter, moving past headwinds that weighed on it for the better part of the last year and a half. This balance is key to Paysign's success, with a steady cash generative core supporting a faster growing high-margin platform.
Through the first half of 2026, the company has channeled more than $900 million in financial assistance to patients. For context, they provided close to $1 billion over the whole of 2025, and have already come within reach of that full year figure in just six months. The pace reflects both widening program base and increased utilization within programs that have now been live for a year or more.
Mr. Newcomer highlighted the significance of Paysign's dynamic business rules technology, which has shielded clients from more than $300 million in costs that co-pay maximizers and accumulator programs would otherwise have diverted. This reflects both the scale of the platform and the continued sharpening of detection logic.
The company launched 13 new programs in the second quarter and exited the quarter with 148 active programs, up from 97 a year ago. This demonstrates the growing importance of Paysign's patient affordability solutions and its ability to adapt to evolving market needs.
